Galapagos is a comprehensive biopharmaceutical company with R&D, production and sales capabilities, dedicated to the discovery, development and commercialization of innovative drugs.It is committed to developing drugs to treat diseases with highly unmet needs to improve the lives of patients around the world.

Its R&D capabilities cover a variety of drug forms, including small molecule, macromolecular and cell therapies.Most of its product portfolio has entered Phase III, including the development of indications such as inflammation, tumors, and fibrosis.The first rheumatoid arthritis and ulcerative colitis drugs have been approved for sale in Europe, the United Kingdom and Japan.

In July 2019, Gilead Sciences and Galapagos jointly announced that the two sides have signed a 10-year global R&D cooperation.Under the terms of the agreement, Galapagos will receive an advance payment of US33.95 billion and an equity investment of US11.1 billion from Gilead.After the investment, Gilead Sciences increased its stake in Galapagos to 22%.

Xianbo Biological is committed to bringing innovative cell therapy products to cancer patients.Xianbo Biological has a rich R&D pipeline, including clinical and preclinical projects.

Dr. Reddy’s Laboratories established in 1984, headquatered in Hyderābād State.  Dr. Reddy’s Laboratories serve customers around the world through our businesses of Active Pharmaceutical Ingredients (API), generics, branded generics, biosimilars and over-the-counter pharmaceutical products.

Dr. Reddy’s Laboratories focus on patient needs in the areas of gastro-enterology, cardiovascular, diabetology, oncology, pain management and dermatology. They are actively developing a pipeline of novel small molecules in immuno-oncology. They are working on a pipeline of differentiated products that improve existing therapeutic agents. They are also investing in emerging areas such as digital therapeutics, cell and gene therapies, among others.